# A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

> **NCT03595059** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 168 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ABBV-155
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03595059
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-13
- **Primary completion:** 2025-09-12
- **Final completion:** 2025-09-12
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595059, "A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03595059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*